-+ 0.00%
-+ 0.00%
-+ 0.00%

Fast Track’s reverSASP Therapeutics signs aging-disease drug R&D pact with GMO Internet Group

PUBT·09/02/2026 23:39:34
Listen to the news
Fast Track’s reverSASP Therapeutics signs aging-disease drug R&D pact with GMO Internet Group
  • Fast Track Initiative portfolio company reverSASP Therapeutics signed a joint R&D deal with GMO Internet Group on aging-related disease drugs.
  • Partnership targets development and commercialization of reverSASP’s GLS1 inhibitor program, using GMO’s AI and machine-learning capabilities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fast Track Initiative Inc published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.